Monitoring gastric cancer progression with circulating tumour DNA

T. Hamakawa; Y. Kukita; Y. Kurokawa; Y. Miyazaki; T. Takahashi; M. Yamasaki; H. Miyata; K. Nakajima; K. Taniguchi; S. Takiguchi; M. Mori; Y. Doki; K. Kato

doi:10.1038/bjc.2014.609

Monitoring gastric cancer progression with circulating tumour DNA

T. Hamakawa, Y. Kukita, Y. Kurokawa, Y. Miyazaki, T. Takahashi, M. Yamasaki, H. Miyata, K. Nakajima, K. Taniguchi, S. Takiguchi, M. Mori, Y. Doki, K. Kato

Research output: Contribution to journal › Article › peer-review

82 Citations (Scopus)

Abstract

Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.

Original language	English
Pages (from-to)	352-356
Number of pages	5
Journal	British journal of cancer
Volume	112
Issue number	2
DOIs	https://doi.org/10.1038/bjc.2014.609
Publication status	Published - Jan 20 2015
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2014.609

Cite this

@article{e3f5aea423eb4f1794d49e876eef324b,

title = "Monitoring gastric cancer progression with circulating tumour DNA",

abstract = "Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.",

author = "T. Hamakawa and Y. Kukita and Y. Kurokawa and Y. Miyazaki and T. Takahashi and M. Yamasaki and H. Miyata and K. Nakajima and K. Taniguchi and S. Takiguchi and M. Mori and Y. Doki and K. Kato",

year = "2015",

month = jan,

day = "20",

doi = "10.1038/bjc.2014.609",

language = "English",

volume = "112",

pages = "352--356",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Monitoring gastric cancer progression with circulating tumour DNA

AU - Hamakawa, T.

AU - Kukita, Y.

AU - Kurokawa, Y.

AU - Miyazaki, Y.

AU - Takahashi, T.

AU - Yamasaki, M.

AU - Miyata, H.

AU - Nakajima, K.

AU - Taniguchi, K.

AU - Takiguchi, S.

AU - Mori, M.

AU - Doki, Y.

AU - Kato, K.

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.

AB - Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.

UR - http://www.scopus.com/inward/record.url?scp=84921939213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921939213&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.609

DO - 10.1038/bjc.2014.609

M3 - Article

C2 - 25490524

AN - SCOPUS:84921939213

SN - 0007-0920

VL - 112

SP - 352

EP - 356

JO - British journal of cancer

JF - British journal of cancer

IS - 2

ER -

Monitoring gastric cancer progression with circulating tumour DNA

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this